ALDER BIOPHARMACEUTICALS INC. overview

SHAREHOLDER ALERT: WeissLaw LLP Investigates Alder Biopharmaceuticals, Inc. PR Newswire NEW YORK, Sept. 17, 2019 NEW YORK , Sept. 17, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Alder Biopharmaceuticals, Inc. ("Alder" or the "Company") (NASDAQ: ALDR) in connection with the proposed acquisition of the Company by H. Lundbeck A/S ("H. Lundbeck," OTCMKTS: HLUYY), a Danish pharmaceutical company. Under the terms of...

Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) on Behalf of Alder Shareholders and Encourages Alder Investors to Contact the Firm PR Newswire NEW YORK, Sept. 16, 2019 NEW YORK , Sept. 16, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) on behalf of Alder shareholders concerning the proposed merger with H. Lundbeck...

Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Alder BioPharmaceuticals has obtained a Fair Price in its sale to H. Lundbeck A/S PR Newswire MILWAUKEE, Sept. 16, 2019 MILWAUKEE , Sept. 16, 2019 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating Alder (Nasdaq: ALDR) for possible breaches of fiduciary duty and other violations of the law in connection with the sale of Alder to H. Lundbeck. Click here to learn how to join the action:...

Alder (ALDR) Alert: Johnson Fistel Investigates Proposed Sale of Alder BioPharmaceuticals, Inc.; Are Shareholders Getting a Fair Deal? PR Newswire SAN DIEGO, Sept. 16, 2019 SAN DIEGO , Sept. 16, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) ("Alder") breached their fiduciary duties in connection with the proposed sale of the Company to Danish pharmaceutical company...

Bolt Biotherapeutics Appoints Veteran Executive Randall Schatzman as CEO to Lead the Next Phase of Growth -- Immune-stimulating Antibody Conjugate (ISAC) Immunotherapy Technology Attracts Seasoned Biotech Business Leader -- PR Newswire REDWOOD CITY, Calif., Sept. 4, 2019 REDWOOD CITY, Calif. , Sept. 4, 2019 /PRNewswire/ -- Bolt Biotherapeutics, Inc., a private biotechnology company focused on unleashing the power of the immune system to treat cancer, today announced that it has appointed Randall...

NEW YORK, NY / ACCESSWIRE / February 26, 2018 / Alder Biopharmaceuticals, Inc. (NASDAQ: ALDR ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 26, 2018 at 5:00 PM Eastern Time. To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/company/23363 To receive updates for this company you can register by emailing [email protected] or by clicking get investment info from the company's profile. About Investor...

Are the moves in Alder Biopharmaceuticals giving you a headache? Last year was tough for the company, but this year it's telling a different story. Jim Cramer got the latest from the drugmaker's......